Meeting to Tackle Drug Development Challenges for Idiopathic Hypersomnia
The Illuminate Hypersomnia Adjunct Scientific Meeting on Feb 13, 2025, will address challenges in idiopathic hypersomnia drug development.
Category: Idiopathic Hypersomnia
Idiopathic Hypersomnia
Latest
Idiopathic Hypersomnia
Latest
Jazz to Highlight Narcolepsy and IH Research at AAN 2024
The research includes an oral presentation revealing that individuals with idiopathic hypersomnia experienced higher odds of comorbid conditions, such as cardiovascular disease.
Idiopathic Hypersomnia
Latest
Pathophysiology of Idiopathic Hypersomnia
Research has revealed potential clues into the pathophysiology of idiopathic hypersomnia.
Jazz Spotlights Heart Risks Linked to Narcolepsy and Idiopathic Hypersomnia
At World Sleep 2023, Jazz Pharmaceuticals will spotlight the link between sleep disorders and cardiovascular health through 14 abstracts.
Read More
Pitolisant Misses Primary Endpoint in Phase 3 Study for IH
Topline results from the INTUNE study of pitolisant for idiopathic hypersomnia revealed that the primary endpoint for excessive daytime sleepiness did not achieve statistical significance against a placebo in the randomized withdrawal phase.
Read More
IH Drug Candidate Well-Tolerated Across Doses, Interim Data Shows
Interim data from Zevra Therapeutics’ phase 2 clinical trial of KP1077 in patients with idiopathic hypersomnia indicates the drug is well-tolerated at all tested doses and dosing schedules.
Read More
Jazz: Oxybate Enhances Sleep Quality in Narcolepsy Patients Regardless of Dosing Schedule
The review evaluated all high-sodium oxybates, fixed-dose, and twice-nightly administrations in both oxybate-experienced patients and those who had not undergone prior treatment.
Read More
KP1077 Rivals Ritalin in Heart Safety for Idiopathic Hypersomnia
Zevra Therapeutics highlighted the heart safety of serdexmethylphenidate, the main ingredient in KP1077, its potential treatment for idiopathic hypersomnia, during a poster presentation at Psych Congress 2023.
Read More
Harmony Gets FDA Orphan Drug Designation for Pitolisant for Idiopathic Hypersomnia
Harmony Biosciences is currently evaluating the efficacy and safety of pitolisant in adult patients with idiopathic hypersomnia in a phase 3 study, with topline results anticipated in the fourth quarter.
Read More
Initiative Provides Financial Assistance to Idiopathic Hypersomnia Patients
Financial assistance from The Assistance Fund is now available for eligible people living with idiopathic hypersomnia.
Read More
NLS Eyes Fast-Track Designation for Mazindol ER for Narcolepsy
NLS Pharmaceutics issued a letter updating stakeholders on its progress in developing treatments for sleep disorders, which include Mazindol ER for narcolepsy, NLS-4 for idiopathic hypersomnia, and NLS-11 for Kleine-Levin Syndrome.
Read More
Zevra Advances KP1077 for Idiopathic Hypersomnia and Narcolepsy in Q2
Zevra Therapeutics provided second-quarter corporate updates, showcasing progress for KP1077, a drug candidate being investigated for the treatment of idiopathic hypersomnia and narcolepsy.
Read More
Low-Sodium Xywav Leads Jazz Pharma’s Oxybate Revenues
During the second quarter, Jazz Pharmaceuticals registered a 39% year-over-year growth in net product sales of its low-sodium Xywav.
Read More
Wakix Hits Record High Prescription Demand in Q2
Harmony Biosciences reported second-quarter business updates, showcasing an upswing in prescription demand for its narcolepsy drug, Wakix.
Read More
Harmony Biosciences Names Recipients of Patients and Progress at the Heart Awards
Harmony Biosciences selected the latest round of nonprofit organizations for its Patients at the Heart and Progress at the Heart awards, which provide funding toward interdisciplinary community initiatives that address challenges facing people living with sleep disorders and rare neurological diseases.
Read More
Jazz to Present Seven Abstracts on Idiopathic Hypersomnia and Narcolepsy
Jazz Pharmaceuticals is presenting seven abstracts featuring new data from across its sleep medicine portfolio, encompassing idiopathic hypersomnia and narcolepsy.
Read More
Harmony Hits Enrollment Target Early for Phase 3 Study of Pitolisant for IH
The phase 3 registrational INTUNE study will evaluate the safety and efficacy of pitolisant in adult patients with idiopathic hypersomnia.
Read More
Patient-Led Initiative to Propel Development of Sleep Disorder Treatments
The program will provide researchers with the opportunity to request and analyze high-quality data and enable individuals with primary central disorders of hypersomnolence to share their data.
Read More